Company Profile

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company

20/04	F-star Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01/12	F-Star Therapeutics, Inc. Announces Termination of Ryan William Fiehler as Director, Effective December 1, 2025	CI
20/10/25	F-star Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
04/04/25	John Edward Lash of United States of America and The management of F-star Therapeutics, Inc. acquired F-star Therapeutics, Inc. from invoX Pharma Limited in a management buyout transaction.	CI
29/12/24	F-star Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
28/12/24	F-star Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
29/09/23	F-star Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
05/07/23	F-Star Entered into Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generationmulti-Specific Antibodies	CI
22/03/23	F-Star Announces Licence Agreement with Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody	CI
10/03/23	F-star Therapeutics, Inc.(NasdaqCM:FSTX) dropped from S&P TMI Index	CI
10/03/23	F-star Therapeutics, Inc.(NasdaqCM:FSTX) dropped from S&P Global BMI Index	CI
09/03/23	F-star Therapeutics Gets Acquired by invoX Pharma for $161 Million	MT
09/03/23	F-star Therapeutics, Inc.(NasdaqCM:FSTX) dropped from NASDAQ Composite Index	CI

15/07/22	HC Wainwright Downgrades F-star Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $35	MT
24/06/22	SVB Securities Downgrades F-star Therapeutics to Market Perform From Outperform; Price Target is $7	MT
24/06/22	Laidlaw Downgrades F-star Therapeutics to Hold From Buy	MT
24/06/22	Ladenburg Thalmann Downgrades F-star Therapeutics to Neutral From Buy	MT
24/06/22	William Blair Downgrades F-star Therapeutics to Market Perform From Outperform Rating	MT

10/03/23	F star Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
10/03/23	F-STAR THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
09/03/23	InvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.	BU
08/03/23	F-STAR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
08/03/23	F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma	AQ

06/01/22	Merck-Tochter übt vierte Option in F-Star-Therapeutics-Kooperation aus
01/04/21	F-Star Therapeutics : Merck KGaA übt Option für mehr Kooperation aus

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/3/23	Geoff Race	Tender	Director	43,937	0.1999%
8/3/23	Louis Kayitalire	Tender	Chief Technology Officer	183,777	0.8360%
8/3/23	Edward Benz	Issuer sale	Director	48,322	0.2198%

F-star Therapeutics, Inc. Stock

Stocks

FSTX

US30315R1077

Biotechnology & Medical Research

Latest news : F-star Therapeutics, Inc.

Analysts' recommendations: F-star Therapeutics, Inc.

Press Releases: F-star Therapeutics, Inc.

News in other languages: F-star Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
F-STAR THERAPEUTICS, INC.	-.--%	+27.14%	-	-	157M
WUXI APPTEC CO., LTD.	-3.25%	+13.72%	+52.49%	+88.86%	62.92B
ARGENX SE	+2.87%	+4.08%	+34.66%	+75.39%	54.32B
BIONTECH SE	-1.07%	-1.79%	-18.07%	-14.36%	22.91B
INSMED INCORPORATED	+33.86%	+30.60%	+19.14%	+502.77%	28.73B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	21.65B
GENMAB A/S	+9.27%	+9.98%	+41.31%	-19.56%	17.76B
PHARMAESSENTIA CORPORATION	-3.37%	+25.85%	+213.21%	+369.13%	16.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	15.48B
EXELIXIS, INC.	-7.94%	-6.74%	+38.42%	+157.52%	13.12B
Average	+4.74%	+8.08%	+52.10%	+205.14%	28.15B
Weighted average by Cap.	+4.87%	+8.61%	+46.40%	+166.78%